GAIN THERAPEUTICS, INC Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent
GAIN THERAPEUTICS, INC (GANX) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent of -$61.35 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-06-30 was -$61.35K.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2026-03-31 was $767.00.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-12-31 was -$161.15K, a 218.49% decline year-over-year.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for the quarter ending 2025-09-30 was -$5.31K.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2025 was -$177.21K, a 233.72% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2024 was $132.52K, a 3.86% increase from fiscal 2023.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2023 was $127.60K.
- GAIN THERAPEUTICS, INC other comprehensive (income) loss, defined benefit plan, after tax and reclassification adjustment, attributable to parent for fiscal 2022 was -$227.13K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 3 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 6 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 9 month | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$61.35K 10-Q · filed 2026-08-11 | -$60.59K 10-Q · filed 2026-08-11 | -$221.73K derived: sum of 3 quarters · filed 2026-08-11 | -$227.04K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $767.00 10-Q · filed 2026-05-11 | -$160.38K derived: sum of 2 quarters · filed 2026-05-11 | -$165.69K derived: sum of 3 quarters · filed 2026-05-11 | -$171.62K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$161.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$166.45K derived: sum of 2 quarters · filed 2026-03-26 | -$172.39K derived: sum of 3 quarters · filed 2026-08-11 | -$177.21K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$5.31K 10-Q · filed 2025-11-12 | -$11.24K derived: sum of 2 quarters · filed 2026-08-11 | -$16.07K 10-Q · filed 2025-11-12 | $119.93K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.93K 10-Q · filed 2026-08-11 | -$10.76K 10-Q · filed 2026-08-11 | $125.24K derived: sum of 3 quarters · filed 2026-08-11 | $123.94K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$4.83K 10-Q · filed 2026-05-11 | $131.18K derived: sum of 2 quarters · filed 2026-05-11 | $129.87K derived: sum of 3 quarters · filed 2026-05-11 | $128.78K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $134.70K derived: sum of 2 quarters · filed 2026-03-26 | $133.61K derived: sum of 3 quarters · filed 2026-03-26 | $132.52K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$1.30K 10-Q · filed 2025-11-12 | -$2.39K derived: sum of 2 quarters · filed 2025-11-12 | -$3.48K 10-Q · filed 2025-11-12 | $122.11K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.09K 10-Q · filed 2025-08-12 | -$2.18K 10-Q · filed 2025-08-12 | $123.41K derived: sum of 3 quarters · filed 2025-08-12 | $124.06K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.09K 10-Q · filed 2025-05-14 | $124.50K derived: sum of 2 quarters · filed 2025-05-14 | $125.14K derived: sum of 3 quarters · filed 2025-05-14 | $125.84K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $125.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $126.23K derived: sum of 2 quarters · filed 2025-03-27 | $126.93K derived: sum of 3 quarters · filed 2025-03-27 | $127.60K 10-K · filed 2025-03-27 |
| 2023-09-30 | $642.00 10-Q · filed 2024-11-14 | $1.34K derived: sum of 2 quarters · filed 2024-11-14 | $2.01K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $700.00 10-Q · filed 2024-08-08 | $1.37K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $670.00 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$227.13K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |